Thailand's new government is reportedly set to reconsider its aggressive stance on compulsory licenses for patented pharmaceuticals as it faces the threat of trade sanctions from the United States.
An investor who allegedly made almost $30,000 in one week last year by acting on inside information concerning a Chemed Corp. quarterly earnings statement has settled the U.S. Securities and Exchange Commission's complaint.
Proposed class action suits are piling up against Merck & Co. and Schering-Plough Corp., claiming the drugmakers broke state consumer protection laws through the sale and marketing of cholesterol-lowering drugs Vytorin and Zetia.
Medical device maker Lumenis Ltd. has announced a proposed $20.1 million deal to settle a long-running class action by shareholders who accused the company of making false boasts about demand for its products.
A Missouri appellate court has ruled that state courts have the authority to ensure that private hospitals follow their state-mandated bylaws, allowing physicians to sue hospitals over staffing decisions for the first time in more than 40 years.
A jury has said Novartis AG unit CIBA Vision Corp. must pay $41 million for allegedly violating a Rembrandt Vision Technologies LP patent for a treatment that allows users to wear their contact lenses for extended periods.
Energy Transportation Group Inc. has won a $31 million verdict against two corporate members of an allegedly anti-competitive trade association that were found to have infringed two of its hearing aid technology patents.
In an attempt to stave off the launch of a generic copy of its top-selling anti-psychotic drug Seroquel, AstraZeneca Pharmaceuticals LP has asked a federal court for permission to file a summary judgment motion in its spat with generics drugmaker Teva Pharmaceutical USA Inc.
A lawsuit filed by Schering Corp. against generics maker Anchen Pharmaceuticals Inc. in California has been added to multidistrict litigation in New Jersey concerning the $722 million annual market for Schering's seasonal allergy treatment Clarinex.
Still smarting from recent public scrutiny from a consumer advocacy group over Botox, Allergan Inc. has been hit with more bad news. The U.S. Food and Drug Administration announced Friday it will conduct a safety review of the popular cosmetic treatment and a similar product, Myobloc, after receiving reports of deaths and breathing problems in some patients.
The U.S. Food and Drug Administration may have removed a veterinarian from her post at the agency in response to pressure from Wyeth Pharmaceuticals, a comprehensive congressional report has revealed.
Smith & Nephew Inc. has invalidated three claims of Synthes USA’s bone plating system patent, but the orthopedic device maker was not so successful in challenging a dozen other claims.
A judge will consider in April whether to give the final OK to a proposed $6 million settlement of a class action alleging that Martek Biosciences Corp. violated securities laws and misled investors.
Merck & Co. will pay more than $650 million to settle False Claims Act suits that accused the company of overcharging Medicare and paying kickbacks to doctors to get them to dispense the drugs Mevacor, Vioxx, Zocor and Pepcid.
Novartis AG subsidiary Hexal AG is planning to appeal a German court’s ruling banning the company from selling its laxative product containing macrogol, a company spokesman said Thursday.
Patent protection for Merck & Co.'s Fosamax expired on Wednesday, giving other pharmaceutical companies the thumbs-up to start marketing generic versions of the popular osteoporosis drug.
Two Democratic lawmakers are questioning companies that were involved in the production of direct-to-consumer advertising as part of a congressional investigation into Pfizer Inc.'s use of celebrity doctor Robert Jarvik to plug its blockbuster cholesterol drug Lipitor in TV commercials.
A Nevada judge has nixed Wyeth Pharmaceuticals Inc.'s bid for a new trial in a case that ended in a jury verdict awarding $134 million to three breast cancer sufferers allegedly sickened by the company's hormone replacements.
The U.S. Food and Drug Administration said Wednesday it would be taking enforcement action against companies that market unapproved injectable colchicine in the wake of a slew of deaths related to the drug, which is used to treat gout and other ailments.
In an attempt to put to rest an ongoing legal dispute between Bayer AG and minority shareholders of Bayer acquisition Schering AG, a German court on Thursday reportedly proposed a settlement.